AbbVie's head of global head of immunology discovery research says the ability to profile patients at the molecular level has the potential to dramatically change treatment for people living with chronic conditions.
New testing means patients no longer 'defined by their symptoms'
February 26, 2019 Latest NewsBioPharmaDispatch ExecutiveLatest Video
New Stories
-
The Week in Review Podcast - 19 April
April 19, 2024 - - Podcast -
New Novartis-backed report identifies nuclear medicine opportunity but calls for change
April 19, 2024 - - Latest News -
Scope of practice review recommends formation of new committee
April 19, 2024 - - Latest News -
The HTA review reference committee members should ask themselves one question
April 18, 2024 - - Latest News -
If coercion and retribution are bad for supermarket customers, they must be bad for patients
April 18, 2024 - - Latest News -
AbbVie announces the appointment of new Australia-NZ human resources director
April 18, 2024 - - BioPharma -
'Under Karen’s leadership our local business has thrived both commercially and culturally'
April 18, 2024 - - Latest News